RxDoctor Payments Data

Barbara Moscoso

Internal Medicine · Hialeah, FLNPI 1770999286

Payments from drug & device makers

$123,141in general payments, 2019–2025

Across 24 payments — averaging $5130.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Inc.$123K
  • Lilly USA, LLC$123
$279in research payments, 2019–2025

Across 4 payments — averaging $69.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Corcept Therapeutics$279

What the payments were for

  • Food & beverage$123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mylan Inc.17$123,018
Lilly USA, LLC7$123

How this compares

$123,141 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$13,571
Medicare patients
25
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$37,009
JanuviaSitagliptin Phosphate14$15,190
EliquisApixaban11$11,120
SymbicortBudesonide/Formoterol Fumarate22$6,519
Dexlansoprazole DrDexlansoprazole19$4,802
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,786
Omeprazole87$1,407
Albuterol Sulfate HfaAlbuterol Sulfate33$1,225
Clobetasol Propionate16$1,100
Esomeprazole Magnesium16$1,050
Omega-3 Acid Ethyl Esters13$848
Memantine Hcl35$825
Clorazepate Dipotassium16$807
Famotidine44$659
Fluticasone Propionate41$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$123$37,00927 claims
Mylan Inc.Atorvastatin Calcium$123,018$35669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →